We are a Madison-based, non-profit medical research organization founded in 2014 by Bill Linton, CEO and Founder of Promega Corporation and Dr. Malynn Utzinger, Director Integrative Practices at Promega Corporation. The Institute was founded not long after Bill was inspired by the meaningful impact a psilocybin study had on a friend suffering from cancer.
“Our objective is to find new and effective methods to relieve anxiety and suffering, and contribute to the understanding of neuroscience and the relationship of the mind and body. This is a frontier of research that will shape our future in important ways that we are just beginning to appreciate.”
Board of Directors
Craig J. Christianson, JD, MS
Richard J. Langer (Emeritus Director)
William A. Linton
Scientific Advisory Board
Charles L. Raison, MD
Gary Tarpley (Chair), PhD, MS
Franz X. Vollenweider, MD
The University of Wisconsin Hospital and Clinics
University of Wisconsin–Madison School of Pharmacy
The Heffter Research Institute
The Swiss Neuromatrix Foundation
Roland Griffiths, PhD, Johns Hopkins University School of Medicine
Matthew Johnson, PhD, Johns Hopkins University School of Medicine
Joshua Woolley, MD, UCSF School of Medicine
Brian Anderson, MD, UCSF School of Medicine
Charles Grob, MD, Harbor-UCLA Medical Center
Stephen Ross, MD, New York University (NYU)
Michael Bogenschutz, MD, New York University (NYU)
Franz Vollenweider, MD, University of Zürich
Statement on Collaboration
Usona Institute is able to accomplish its mission of enabling and supporting psychedelic research and FDA registration of psilocybin therapy only through collaboration with many scientists, clinicians, research centers, expert consultants, and philanthropists globally.
Usona will continue to build relationships and collaborations with all organizations that share our philosophy of delivering approved therapies to those in need based on safety, high quality active drug materials, and highly-trained guides and practitioners, at the lowest possible cost.
Usona is building an advanced chemistry capability with our cGMP contract suppliers and through approved research chemistry facilities at two locations in the United States. High quality materials will be supplied to qualified research and therapy centers for basic, applied, and clinical research at cost or gratis, for the purpose of accelerating the pace of research for these important therapies.
Expertise on the Usona team includes:
- Study design and protocol development
- ICH GCP (Good Clinical Practice) compliance
- FDA drug development
- Clinical research leadership
- Multi-site drug development management
- Contract research organization (CRO) management
- CIIS-trained guide expertise
- Complex clinical drug development program management
- Small molecule design and scale-up with full analytical capabilities
- Preclinical safety and pharmacology research
- Translational methodologies
- Navigation of regulatory agencies and requirements
- Public health policy
Per the policy adopted by its Board of Directors, Usona Institute will reimburse indirect costs at a rate of up to 22.5% for clinical research, and a rate of up to 15% for non-clinical research. This policy does not apply to gifts made to research institutions and/or affiliated non-profit entities, which are to be used only toward direct costs.